

Alfredo Tartarone

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2806539/alfredo-tartarone-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56
papers

631
citations

14
h-index

24
g-index

60
ext. papers

777
ext. citations

3.4
avg, IF

4.05
L-index

#	Paper	IF	Citations
56	Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. <i>European Urology</i> , 2005 , 47, 449-54; discussion 454-5	10.2	72
55	Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. <i>European Journal of Haematology</i> , 2007 , 79, 53-8	3.8	60
54	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2019 , 15, 2423-2433	3.6	48
53	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. <i>Lung Cancer</i> , 2013 , 81, 328-336	5.9	45
52	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 86, 42-51	7	36
51	Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. <i>Therapeutic Advances in Respiratory Disease</i> , 2015 , 9, 242-50	4.9	35
50	Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. <i>Future Oncology</i> , 2015 , 11, 2043-8	3.6	26
49	Cardiovascular risk of smoking and benefits of smoking cessation. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3866-3876	2.6	26
48	Progress and challenges in the treatment of small cell lung cancer. <i>Medical Oncology</i> , 2017 , 34, 110	3.7	22
47	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 505-12	2.8	20
46	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2016 , 17, e173-e177	4.9	19
45	CD38 expression does not change in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 3052-3	2.2	18
44	Prevention of high-dose melphalan-induced mucositis by cryotherapy. <i>Leukemia and Lymphoma</i> , 2005 , 46, 633-4	1.9	15
43	COVID-19 and cancer care: what do international guidelines say?. <i>Medical Oncology</i> , 2020 , 37, 80	3.7	15
42	Possible applications of circulating tumor cells in patients with non small cell lung cancer. <i>Lung Cancer</i> , 2017 , 107, 59-64	5.9	13
41	Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094	3.3	13
40	Long-term survival in small cell lung cancer: a case report and review of the literature. <i>Future Oncology</i> , 2014 , 10, 523-8	3.6	11

39	Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 669-72	3.2	11
38	Anal metastasis from breast cancer: a case report and review of the literature. <i>Future Oncology</i> , 2012 , 8, 333-6	3.6	10
37	Linezolid-induced bradycardia: a case report. <i>International Journal of Antimicrobial Agents</i> , 2004 , 23, 412-413	3.3	10
36	Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. <i>Oncology Letters</i> , 2013 , 5, 1741-1743	2.6	9
35	Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1489-90	1.9	8
34	Focus on lung cancer screening. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3815-3820	2.6	8
33	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1391-S1396	2.6	6
32	Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab. <i>Leukemia and Lymphoma</i> , 2003 , 44, 561-2	1.9	6
31	Fibrinolytic, platelet and monocyte variables in homozygous familial hypercholesterolemia. The effect of a regular plasma cholesterol removal by LDL-apheresis. <i>Fibrinolysis</i> , 1993 , 7, 63-64		6
30	Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know. <i>Future Oncology</i> , 2009 , 5, 837-41	3.6	6
29	Somatostatin Analog Therapy in Small Cell Lung Cancer. <i>Seminars in Nuclear Medicine</i> , 2016 , 46, 239-42	5.4	6
28	Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 995-1006	4.4	6
27	When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 761-3	3.5	5
26	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. <i>Medical Oncology</i> , 2014 , 31, 78	3.7	4
25	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. <i>Medical Oncology</i> , 2012 , 29, 3198-201	3.7	4
24	Is there a role for immunotherapy in malignant pleural mesothelioma?. <i>Medical Oncology</i> , 2018 , 35, 98	3.7	4
23	Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1359-S1363	2.6	3
22	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. <i>Medical Oncology</i> , 2012 , 29, 1599-605	3.7	3

21	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. <i>Translational Lung Cancer Research</i> , 2021 , 10, 80-92	4.4	3
20	Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study. <i>Tumori</i> , 2005 , 91, 131-4	1.7	3
19	Improvement of B-cell chronic lymphocytic leukemia during haemodialysis: possible role for endogenous production of factors involved in angiogenesis and apoptosis?. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1263-5	1.9	2
18	Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy. <i>The Hematology Journal</i> , 2004 , 5, 453-5		2
17	Primary gastric lymphoma for stage I/II1 E: operative and conservative management in retrospective data from 71 cases. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1259-61	1.9	2
16	Role of Parenteral Nutrition in Cancer Patients Undergoing High-Dose Chemotherapy Followed by Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Tumori</i> , 2005 , 91, 237-240	1.7	2
15	New cancer drugs: the Italian unsatisfactory solution. <i>Annals of Oncology</i> , 2014 , 25, 1448	10.3	1
14	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. <i>Future Oncology</i> , 2013 , 9, 127-33	3.6	1
13	Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. <i>Future Oncology</i> , 2010 , 6, 1937-40	3.6	1
12	Reflections about off-label use of anticancer drugs. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 604	3.2	1
11	Quantitative evaluation of CD52 expression in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1255-7	1.9	1
10	Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM). <i>Journal of Clinical Nursing</i> , 2020 , 29, 119-129	3.2	1
9	Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation. <i>Tumori</i> , 2005 , 91, 237-40	1.7	1
8	Octogenarians may benefit from stage-specific small cell lung cancer treatment. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3973-3982	4.4	0
7	Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. 2022 , 39, 107		0
6	The era of a "liquid biopsy" may be on the horizon in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1322	2.6	
5	Contractile reserve as a marker of preclinical cardiotoxicity. <i>Journal of Clinical Oncology</i> , 2010 , 28, e769	2.2	
4	Response to de Gramont regimen in small cell lung cancer: a case report. <i>Lung Cancer</i> , 2004 , 43, 375-6	5.9	

- 3 The predictive role of HER2 overexpression in early breast cancer. *Journal of Clinical Oncology*, **2003**, 21, 3179-80; author reply 3180 2.2
- 2 Management of oligoprogression in non-small cell lung cancer patients.. *Medical Oncology*, **2022**, 39, 56 3.7
- 1 Pulmonary blastoma after liver transplant: a case report. *Tumori*, **2002**, 88, 173-5 1.7